Cytokines in systemic lupus erythematosus: their role in pathogenesis of disease and possible therapeutic opportunities

Document Type: Review

Authors

1 Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

4 Network of Immunity in Infection, Malignancy and Autoimmunity, Universal Scientific Education and Research Network, Tehran, Iran

5 Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

6 Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that may involve several organs. The disease is characterized by a recurring pattern of remission and flare. Immunologic factors seem to have important roles in the pathogenesis of SLE. Several studies revealed that cytokines are important in pathogenesis of this disorder. These cytokines include B cell activating factor (BAFF), tumor necrosis factor (TNF), interferon (IFN), interleukin (IL)-23, IL-17, IL-10, IL-6 and IL-21. In this article, the role of cytokines and their encoding genes are described and therapeutic applications have been discussed briefly. 

Keywords

Main Subjects


Shu Man Fu, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmune 2011; 37(2): 104-112. doi: 10.1016/j.jaut.2011.05.004.

Namazi S, Ziaee V, Rezaei N. The role of cytokines in systemic lupus erythematosis: review article. Tehran Univ Medical J 2015; 73(6): 397- 404.

Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384 (9957): 1878-88. doi: 10.1016/s0140-6736(14)60128- 8.

Tobón GJ, Izquierdo JH, Cañas CA. B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus. Autoimmune Dis 2013; 2013:827254. doi: 10.1155/2013/827254

Ahearn MJ, Liu C, Kao HA, Manzi

S. Biomarkers for systemic lupus erythematosus. Transi Res 2012; 159: 326-342. doi: 10.1016/j.trsl.2012.01.021.

Rottman JB, Willis CR. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Vet Pathol 2010; 47(4):664-76. doi: 10.1177/ 0300985810370005.

Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review. Clin Rev Allergy Immunol 2014; 47(2): 136- 47. doi: 10.1007/s12016-013-8402-y.

Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013; 72 Suppl 2: ii56-61. doi: 10.1136/annrheumdis-2012-202351.

Darrah E, Andrade F. NETs: the missing link between cell death and systemic autoimmune diseases? Front Immunol 2013; 3: 428. doi: 10.3389/fimmu.2012.00428.

Aringer M, Günther C, Lee-Kirsch

MA. Innate immune processes in lupus erythematosus. Clin Immunol 2013; 147(3): 216-222. doi: 10.1016/j.clim.2012.11.012.

Lewis J.E, Man Fu Sand Gaskin F. Autoimmunity, End Organ Damage and the Origin of Autoantibodies and Autoreactive T Cells in Systemic Lupus Erythematosus. Discov Med 2013; 15(81): 85-92.

Shrivastav M and Niewold T.B. Nucleicacid sensors and type I interferon production in systemic lupus erythematosus. Frontier in Immunology 2013; 4(319): 1-10. doi: 10.3389/fimmu.2013.00319.

Fortuna G, Brennan M.T. Systemic Lupus Erythematosus: Epidemiology, Pathophysiology, Manifestations, and Management. Dent Clin N Am 2013; 57: 631-655. doi: 10.1016/j.cden. 2013.06.003.

Conti G, Coppo R and Amore A. Pathogenesis of systemic lupus erythematosus (LES). G Ital Nefrol 2012; 29:84-90.

Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 2012; 11(12): 890-897. doi: 10.1016/ j.autrev.2012.03.004.

Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 2012; 24(6): 651-657. doi: 10.1016/j.coi.2012.10.004.

Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic diseas. Nat Rev Rheumatol 2012; 8: 458-468. doi: 10.1038/nrrheum.2012.75.

Tsokos GC. Mechanisms of Disease Systemic Lupus Erythematosus. N Engl J Med 2011; 365: 2110-2121. doi: 10.1056/NEJMra1100359.

Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci 2014; 15(9):16043-56. doi: 10.3390/ ijms150916043.

Bertsias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. In: Wilhelmus J, Bijlsma J (eds). EULAR Textbook on Rheumatic Diseases. BMJ. 2012; 476-505.

Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481-490.

Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382(9894): 819-31. doi: 10.1177/0961203311426568.

Tandrup Nielsen Ch. Circulating Microparticles in Systemic Lupus Erythematosus. Dan Med J 2012; 59(11): 1-34. doi: 10.1016/S0140- 6736(13)60954-X.

Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus 2012; 21(3): 241- 250.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. J Rheumatol 2001; 28: 2653-2656.

Cooper G, Gilbert K, Greidinger E, James J, Pfau J, Reinlib L, Richardson B and Rose N. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Cien Saude Colet 2009;

14(5): 1865-76.

Pisetsky DS. The immunopathogenesis and immunopathology of systemic lupus erythematosus. In: Schur P.H, Massarotti E.M. Lupus erythematosus: clinical evaluation and treatment. New York: Springer, 2012; 13-26.

Su D.L, Lu Z.M, Shen M.N, Li X, Sun L.Y. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012; 347141: 1-15. doi: 10.1155/2012/347141.

Lee H.M, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol 2010; 676284: 1-5. doi: 10.1155/ 2010/676284.

Hin Yap DY, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosus– from bench to bedside. Nephrology 2013; 18: 243-255. doi: 10.1111/nep.12047.

Apostolidis S.A, Lieberman L.A, Kis-Toth K, Crispin J.C, Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interf Cytok Res 2011; 31(10): 769-779. doi: 10.1089/jir.2011.0029.

Davis L.S, Hutcheson J, Mohan C. The Role of Cytokines in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. J Interf Cytok Res 2011; 31(10): 781- 789. doi: 10.1089/jir.2011.0047.

Ronnblom L, Elkon K.B. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:339-347. doi: 10.1038/nrrheum.2010.64.

Perl A. Systems biology of lupus: Mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity 2010; 43(1): 32-47. doi: 10.3109/08916930903374774.

Scholz JL, Oropallo MA, Sindhava V, Goenka R, Cancro MP. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus. Lupus 2013; 22(4): 350-360. doi: 10.1177/ 0961203312469453.

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine & Growth

Factor Reviews 2013; 24: 203-215. doi: 10.1016/j.cytogfr.2013.04.003.

Karageorgas TP, Tseronis DD, Mavragani CP. Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus: Association with Distinct Clinical Phenotypes. J Biomed Biotechnol 2011; 273907:1- 14. doi: 10.1155/2011/273907.

Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10(6):365-73. doi: 10.1038/nrrheum.2014.33.

Boghdadi G1, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int 2014; 34(9): 1217-23. doi: 10.1007/s00296-014-3020-4.

Eilertsen GO, Nossent JC. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus. Lupus 2014; 23(13): 1383-91. doi: 10.1177/0961203314543914.

Connolly JJ, Hakonarson H. Role of Cytokines in Systemic Lupus Erythematous: Recent Progress from GWAS and Sequencing. J Biomed Biotechnol 2012; 798924: 1-18. doi: 10.1155/2012/798924.

Postal M, Appenzeller S. The role of Tumor Necrosis Factor-alpha (TNF- α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56(3): 537-543. doi: 10.1016/j.cyto. 2011.08.026.

Ziaee V, Tahghighi F, Moradinejad MH, Harsini S, Mahmoudi M, Rezaei A, Soltani S, Sadr M, Aghighi Y, Rezaei N. Interleukin-6, interleukin-1 gene cluster and interleukin-1 receptor polymorphisms in Iranian patients with juvenile systemic lupus erythematosus. Eur Cytokine Netw 2014; 25(2): 35-40. doi: 10.1684/ecn. 2014.0352.

Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011; 116: 227-237. doi: 10.3109/03009734.2011.624649.

Frieri M. Accelerated Atherosclerosis in Erythematosus: Role of Proinflammatory and Therapeutic Approaches. Curr Allergy Asthma Rep 2012; 12: 25-32. doi: 10.1007/s11882-011-0236-1.

Iwata Y, Furuichi K, Kaneko Sh, Wada T. The Role of Cytokine in the Lupus Nephritis. J Biomed Biotechnol 2011; 594809: 1-8. doi:10.1155/2011/594809.

Okamoto A, Fujio K, Okamura T and Yamamoto K. Regulatory T Cell- Associated Cytokines in Systemic Lupus Erythematosus. J Biomed Biotechnol 2011; 463412:1-10. doi: 10.1155/2011/463412.

Rezaei A, Ziaee V, Sharabian FT, Harsini S, Mahmoudi M, Soltani S, Sadr M, Moradinejad MH, Aghighi Y, Rezaei N. Lack of association between interleukin-10, transforming growth factor-beta gene polymorphisms and juvenile-onset systemic lupus erythematosus. Clin Rheumatol 2015; 34(6): 1059-64. doi: 10.1007/s10067-015-2877-2.

Deocharan B, Marambio P, Edelman M, Putterman C. Differential effects of interleukin-4 in peptide induced autoimmunity. Clin Immunol 2003; 108(2): 80-8.

Mahmoudi M, Tahghighi F, Ziaee V, Harsini S, Rezaei A, Soltani S, Sadr M, Moradinejad MH, Aghighi Y, Rezaei N. Interleukin-4 single nucleotide polymorphisms in juvenile systemic lupus erythematosus. Int J

Immunogenet 2014; 41(6): 512-7. doi: 10.1111/iji.12152.

Yu HH, Liu PH, Lin YC, Chen WJ, Lee JH, Wang LC, Yang YH, Chiang BL. Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus 2010; 19(10): 1219-28. doi: 10.1177/ 0961203310371152.

Wu MC, Huang CM, Tsai JJ, Chen HY, Tsai FJ. Polymorphisms of the interleukin-4 gene in chinese patients with systemic lupus erythematosus in Taiwan. Lupus 2003; 12(1): 21-5.

Sarra M, Monteleone G. Interleukin- 21: A new mediator of Inflammation in systemic lupus erythematosus. J Biomed Biotechnol 2010; 294582: 1- 6. doi: 10.1155/2010/294582.

Rajadhyaksha AG, Mehra S, Nadkar MY. Biologics in SLE: The Current Status. APRIL 2013; 61:262-267.

Jordan N, Lutalo PMK, D’Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med 2013; 11: 1-11. doi: 10.1186/1741-7015-11-

120.

Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: Towards new approaches. Best Practice & Research Clin Rheumatol 2013; 27: 341-349. doi: 10.1016/j.berh.2013. 07.006.

Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 2014; 18(4): 473-89. doi: 10.1517/14728222.2014.888415.

Relle M and Schwarting A. Role of MHC-Linked Susceptibility Genes in the Pathogenesis of Human and Murine Lupus. Clin Develop Immunol 2012; 584374: 1-16. doi: 10.1155/2012/584374.

Tiffin N, Adeyemo A, Okpechi I. A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus. Orphanet Journal of Rare Diseases 2013; 8: 1-8. doi: 10.1186/1750- 1172-8-2.